ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
2 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
539
|
188K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Danielguda1
|
99 |
32K |
3 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
99
|
32K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
2 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
539
|
188K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
4 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
539
|
188K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
2 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
539
|
188K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
1 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
539
|
188K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
1 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
539
|
188K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
0 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
539
|
188K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
1 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
539
|
188K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
1 |
16/10/23 |
16/10/23 |
ASX - By Stock
|
539
|
188K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
2 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
539
|
188K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
2 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
539
|
188K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
1 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
539
|
188K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
3 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
539
|
188K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
1 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
539
|
188K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
2 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
539
|
188K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
6 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
539
|
188K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
9 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
539
|
188K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
3 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
539
|
188K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
6 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
539
|
188K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to cohort 3
|
|
Danielguda1
|
65 |
16K |
2 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
65
|
16K
|
2
|
|
ASX - By Stock
|
CU6 |
Research/Valuation
|
|
Danielguda1
|
539 |
188K |
22 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
539
|
188K
|
22
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to cohort 3
|
|
Danielguda1
|
65 |
16K |
4 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
65
|
16K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to cohort 3
|
|
Danielguda1
|
65 |
16K |
4 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
65
|
16K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to cohort 3
|
|
Danielguda1
|
65 |
16K |
8 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
65
|
16K
|
8
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to cohort 3
|
|
Danielguda1
|
65 |
16K |
9 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
65
|
16K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to cohort 3
|
|
Danielguda1
|
65 |
16K |
7 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
65
|
16K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
The FDA is a corrupt organization.
|
|
Danielguda1
|
155 |
57K |
1 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
155
|
57K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
The FDA is a corrupt organization.
|
|
Danielguda1
|
155 |
57K |
3 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
155
|
57K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
Danielguda1
|
138 |
45K |
3 |
16/05/23 |
16/05/23 |
ASX - By Stock
|
138
|
45K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
Danielguda1
|
138 |
45K |
8 |
05/05/23 |
05/05/23 |
ASX - By Stock
|
138
|
45K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Phase 1B brain cancer clinical trial approved for initiation
|
|
Danielguda1
|
13 |
4.0K |
0 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
13
|
4.0K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Phase 1B brain cancer clinical trial approved for initiation
|
|
Danielguda1
|
13 |
4.0K |
2 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
13
|
4.0K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Change of Registry Address
|
|
Danielguda1
|
2 |
920 |
4 |
01/11/22 |
01/11/22 |
ASX - By Stock
|
2
|
920
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
3 |
19/10/22 |
19/10/22 |
ASX - By Stock
|
452
|
160K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
2 |
19/10/22 |
19/10/22 |
ASX - By Stock
|
452
|
160K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
1 |
18/10/22 |
18/10/22 |
ASX - By Stock
|
452
|
160K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
3 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
452
|
160K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
5 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
452
|
160K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
2 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
452
|
160K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
0 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
452
|
160K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
6 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
452
|
160K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
0 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
452
|
160K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
0 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
452
|
160K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
4 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
452
|
160K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
0 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
452
|
160K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
3 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
452
|
160K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
2 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
452
|
160K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
0 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
452
|
160K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Danielguda1
|
452 |
160K |
1 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
452
|
160K
|
1
|
|